SCHEMBL3379635

SCHEMBL3379635

Fc1cncc(-c2cnc(Nc3ccc(Cl)cn3)c3ncccc23)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 6/20 0.39
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 2/20 0.35
AHR P35869 1/20 0.35
KDR P35968 3/20 0.35
FLT1 P17948 2/20 0.35
CYP3A4 P08684 2/20 0.34
CYP17A1 P05093 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
ALDH1A1 P00352 1/20 0.34
PKM P14618 1/20 0.34
TSHR P16473 1/20 0.34
PIK3CA P42336 1/20 0.33
GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3379162 0.90 GRM4 (0.41) GRM4CYP3A4TSHR
SCHEMBL3380176 0.83 GRM4 (0.46) GRM4KDRFLT1CYP3A4CYP17A1
SCHEMBL3378927 0.79 MKNK1 (0.41) GRM4CYP3A4TSHR
SCHEMBL3378893 0.79 CKS1B (0.42) LMNACYP3A4CYP17A1TSHR
SCHEMBL3378849 0.78 ABCG2 (0.42) CYP3A4
SCHEMBL3383117 0.73 GRM4 (0.40) GRM4NPC1CYP3A4CYP17A1CYP11B1
SCHEMBL3380156 0.72 CKS1B (0.47) RAB9AKMT2ANPC1KDRCYP3A4
SCHEMBL13899832 0.70 CKS1B (0.42) GRM4RAB9ASMN1; SMN2NPC1CYP3A4
SCHEMBL3383582 0.69 TDO2 (0.42) RAB9ASMN1; SMN2LMNAKMT2ANPC1
SCHEMBL3379091 0.69 GRM4 (0.49) GRM4KDRFLT1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101277958-B Naphthyridin derivatives HOFFMANN LA ROCHE 2011-09-07 CN disclosed
EP-1934216-B1 NAPHTHYRIDIN DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP disclosed
EP-1934216-B1 NAPHTHYRIDIN DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
CN-101277958-A Naphthyridin derivatives HOFFMANN LA ROCHE (CH) 2008-10-01 CN disclosed
EP-1934216-A1 NAPHTHYRIDIN DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-06-25 EP disclosed
WO-2007039512-A1 NAPHTHYRIDIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078155-A1 Naphthyridin derivatives GRM5, GRM3, GRM1 GRM4 9/4885RAB9A 2594/4885SMN1; SMN2 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.